Neuroone Medical Technologies is trading 5.9% down at $1.31, with no clear company-specific catalyst identified.
- The latest reported company news was a September 17 Southern California distribution agreement for its FDA-cleared OneRF system, which does not directly explain the September 21, 2026 decline.
- The broader market is strongly higher, suggesting the decline appears stock-specific or driven by trading dynamics rather than overall risk sentiment.